Holen Sie sich die Stockscreener-App
39.54
3.96%
-1.63
Handel nachbörslich:
39.16
-0.38
-0.96%
Schlusskurs vom Vortag:
$41.17
Offen:
$38.44
24-Stunden-Volumen:
49,169
Relative Volume:
1.22
Marktkapitalisierung:
$155.73M
Einnahmen:
$17,000
Nettoeinkommen (Verlust:
$-31.08M
KGV:
-11.82
EPS:
-3.3463
Netto-Cashflow:
$-24.86M
1W Leistung:
+7.74%
1M Leistung:
+11.66%
6M Leistung:
+75.03%
1J Leistung:
+143.17%
1-Tages-Spanne:
$38.44
$41.80
1-Wochen-Bereich:
$37.10
$43.09
52-Wochen-Spanne:
$14.00
$44.00
Vtv Therapeutics Inc Stock (VTVT) Company Profile
Firmenname
Vtv Therapeutics Inc
Sektor
Branche
Telefon
336-841-0300
Adresse
3980 PREMIER DR, HIGH POINT, NC
Compare VTVT vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
39.54 | 162.15M | 17,000 | -31.08M | -24.86M | -3.3463 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2026-01-23 | Eingeleitet | Roth Capital | Buy |
| 2026-01-05 | Eingeleitet | TD Cowen | Buy |
| 2025-11-19 | Eingeleitet | BTIG Research | Buy |
| 2019-05-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-04-10 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-08 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-08 | Eingeleitet | Northland Capital | Outperform |
| 2016-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-09-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-08-24 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-08-24 | Eingeleitet | Stifel | Buy |
Alle ansehen
Vtv Therapeutics Inc Aktie (VTVT) Neueste Nachrichten
Earnings Risk: Will vTv Therapeutics Inc face regulatory challengesPortfolio Return Summary & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Why (VTVT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Wall Street Analysts Think vTv Therapeutics (VTVT) Could Surge 31.58%: Read This Before Placing a Bet - sharewise.com
Millennium Management LLC Acquires Shares in vTv Therapeutics Inc - GuruFocus
VTVT Technical Analysis & Stock Price Forecast - Intellectia AI
Aug PostEarnings: How does vTv Therapeutics Inc score in quality rankingsStop Loss & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
vTv Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Analysts’ Opinions Are Mixed on These Healthcare Stocks: vTv Therapeutics (VTVT) and CSPC Pharmaceutical Group (OtherCHJTF) - The Globe and Mail
Millennium Management (NASDAQ: VTVT) reports a 5.0% holding in vTv - Stock Titan
Technical Analysis: Will vTv Therapeutics Inc outperform the market in YEAR2026 EndofMonth & Long Hold Capital Preservation Plans - baoquankhu1.vn
How CRH plc stock performs during market volatility - baoquankhu1.vn
Aug Action: Does vTv Therapeutics Inc have declining or rising EPSEarnings Recap Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
CEO Moves: Is vTv Therapeutics Inc exposed to currency risks2026 Key Highlights & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Understanding Momentum Shifts in (VTVT) - Stock Traders Daily
Guidance Update: Will vTv Therapeutics Inc benefit from green energy policiesInsider Selling & Real-Time Buy Zone Alerts - baoquankhu1.vn
Published on: 2026-03-23 05:09:08 - baoquankhu1.vn
vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
VTV Therapeutics (VTVT) reports $27M 2025 net loss amid cadisegliatin advancements - MSN
VTVT Forecast, Price Target & Analyst Ratings | VTV THERAPEUTICS INC- CL A (NASDAQ:VTVT) - chartmill.com
vTv Therapeutics (VTVT) Reports $27M 2025 Net Loss Amid Cadisegliatin Advancements - Yahoo Finance
Wall Street Analysts Believe vTv Therapeutics (VTVT) Could Rally 39.86%: Here's is How to Trade - Yahoo Finance
vTv Therapeutics to Participate in the 38th Annual ROTH Conference - The Manila Times
VTv Therapeutics to Participate in the 38th Annual ROTH Conference - marketscreener.com
Biotech developing oral type 1 diabetes drug joins ROTH investor event - Stock Titan
Baker BROS. Advisors LP Has $3.46 Million Holdings in vTv Therapeutics Inc. $VTVT - MarketBeat
vTv Therapeutics (NASDAQ:VTVT) Upgraded at Evercore - MarketBeat
Wall Street Zen Upgrades vTv Therapeutics (NASDAQ:VTVT) to "Hold" - MarketBeat
HC Wainwright Raises Earnings Estimates for vTv Therapeutics - Defense World
HC Wainwright Brokers Increase Earnings Estimates for VTVT - Defense World
HC Wainwright Forecasts Higher Earnings for vTv Therapeutics - MarketBeat
This Jabil Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sahm
Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (VTVT) and Oxford BioMedica (OtherOXBDF) - The Globe and Mail
Evercore ISI initiates vTv Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
Evercore ISI Initiates vTv Therapeutics at Outperform With $44 Price Target - marketscreener.com
Evercore ISI Initiates Coverage on VTVT with Outperform Rating | VTVT Stock News - GuruFocus
Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Sarepta Therapeutics (SRPT) and vTv Therapeutics (VTVT) - The Globe and Mail
Research Analysts Set Expectations for VTVT Q1 Earnings - MarketBeat
vTv Therapeutics (NASDAQ:VTVT) Share Price Crosses Below 50-Day Moving AverageShould You Sell? - MarketBeat
vTv Therapeutics (VTVT) Projected to Post Earnings on Thursday - Defense World
Avoiding Lag: Real-Time Signals in (VTVT) Movement - Stock Traders Daily
BTIG Maintains Buy on vTv Therapeutics Inc (VTVT) March 11, 2026 - Meyka
BTIG reiterates Buy on vTv Therapeutics stock, $49 target maintained By Investing.com - Investing.com Canada
VTVT: BTIG Reiterates Buy Rating with Unchanged Price Target | V - GuruFocus
BTIG reiterates Buy on vTv Therapeutics stock, $49 target maintained - Investing.com
vTv Therapeutics 2025 – Pipeline, Clinical Trials, and Patent Portfolio Overview - Minichart
vTv Therapeutics price target raised to $55 from $35 at Alliance Global - TipRanks
VTv Therapeutics: Q4 Earnings Snapshot - theheraldreview.com
vTv Therapeutics Highlights Cadisegliatin Phase 3 and Cash Runway - TipRanks
vTv Therapeutics 2025 10-K: $0.0M Revenue, $(26.97)M Net Loss - TradingView
VTv Therapeutics: Fourth Quarter Earnings Overview - Bitget
vTv Therapeutics Inc 預計每股虧損 81 美分財報前瞻 - TradingView
Finanzdaten der Vtv Therapeutics Inc-Aktie (VTVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):